Category: Accelerate

Boehringer Ingelheim and MD Anderson Expand their Collaboration to Accelerate Targeted Therapies for Lung Cancer

Shots: Boehringer Ingelheim and MD Anderson expand their 2019 joint VRDC to explore new molecules from Boehringer Ingelheim’s KRAS and TRAILR2 portfolios for lung cancer, particularly NSCLC The joint research will continue for 5 additional years. The extended collaboration follows successful preclinical studies in GI cancers via joint VRDC The expanded agreement allows the partners […]

AstraZeneca Collaborates with MGH to Accelerate Digital Health Solutions

Shots: The companies collaborated to accelerate digital health solutions with the goal of improving the patient’s outcomes and care with chronic illness MGH will utilize AstraZeneca’s AMAZE disease management platform for heart failure and asthma management studies. The companies plan to expand the use of AMAZE across multiple chronic diseases, following the success of heart […]

UCB Collaborates with Microsoft to Accelerate Drug Discovery and Development

Shots: The collaboration will merge Microsoft’s computational services, cloud and AI with UCB’s drug discovery and development capabilities The companies intend to discover and develop medicines for people living with severe diseases in immunology and neurology. The collaboration follows UCB and Microsoft’s collaboration around COVID-19 Microsoft will provide AI technology and applied scientists to work […]

Sarepta Therapeutics Collaborates with University of Florida to Accelerate the Development of Therapies for Rare Genetic Diseases

Shots: Sarepta to fund four research programs at the UF and will get an exclusive option to develop any new therapeutic compounds resulting from the funded research programs. The projects include exploratory research in novel gene therapy vectors, next-generation capsids, and gene editing technologies along with new therapeutic areas in degenerative genetic diseases The focus […]

Ovid Therapeutics and University of Connecticut Collaborate to Accelerate the Development of OV101 (gaboxadol) for Angelman Syndrome

Shots: Ovid will collaborate with UConn’s Stormy J. Chamberlain and secures exclusive access to identified genetic sequences for shRNA-based therapy. Ovid plans to leverage its translational medicine capabilities and drug development expertise in Angelman syndrome to advance OV101 into clinical Ovid is developing OV101 for Angelman syndrome to restore tonic inhibition addressing several core symptoms […]